IN2014CN03333A - - Google Patents

Download PDF

Info

Publication number: IN2014CN03333A
Authority: IN; India
Prior art keywords: shk; potassium channel; inhibiting agent; modified; obesity
Prior art date: 2011-10-03

Application number

Other languages

English (en)

Inventor

George K Chandy

Sanjeev Kumar Upadhayay

Ping H Wang

Paolo Sassone Corsi

Kristin Lynn Eckel Mahan

Shawn Iadonato

Joseph Mukergee

Reza M Mirbolooki

Original Assignee

Univ California

Kineta One Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-10-03

Filing date

2012-10-02

Publication date

2015-07-03

2012-10-02 Application filed by Univ California, Kineta One Llc filed Critical Univ California

2015-07-03 Publication of IN2014CN03333A publication Critical patent/IN2014CN03333A/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43595—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Epidemiology (AREA)
Zoology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Obesity (AREA)
Hematology (AREA)
Tropical Medicine & Parasitology (AREA)
Toxicology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Child & Adolescent Psychology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

IN3333CHN2014 2011-10-03 2012-10-02 IN2014CN03333A (ja)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201161542751P	2011-10-03	2011-10-03
PCT/US2012/058495 WO2013052507A1 (en)	2011-10-03	2012-10-02	TREATMENT OF OBESITY AND OBESITY-RELATED DISORDERS BY PHARMACOLOGICAL TARGETING OF Kv1.3 POTASSIUM CHANNELS

Publications (1)

Publication Number	Publication Date
IN2014CN03333A true IN2014CN03333A (ja)	2015-07-03

Family

ID=48044112

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IN3333CHN2014 IN2014CN03333A (ja)	2011-10-03	2012-10-02

Country Status (16)

Country	Link
US (2)	US20150072940A1 (ja)
EP (1)	EP2763702A4 (ja)
JP (1)	JP2014531469A (ja)
KR (1)	KR20140108518A (ja)
CN (1)	CN103987408A (ja)
AU (1)	AU2012318736A1 (ja)
BR (1)	BR112014008065A2 (ja)
CA (1)	CA2850357A1 (ja)
HK (1)	HK1201048A1 (ja)
IL (1)	IL231873A0 (ja)
IN (1)	IN2014CN03333A (ja)
MX (1)	MX2014004029A (ja)
RU (1)	RU2014117558A (ja)
SG (1)	SG11201401193XA (ja)
TW (1)	TW201321403A (ja)
WO (1)	WO2013052507A1 (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2474316B1 (en) *	2004-10-07	2016-04-06	The Regents of The University of California	Analogs of shk toxin and their uses in selective inhibition of kv1.3 potassium channels
JP6250536B2 (ja)	2011-06-06	2017-12-20	ケイ・ブイ・１．３・セラピューティクス・インコーポレイテッド	Ｓｈｋベースの薬学的組成物とその製造方法および使用方法
IN2014CN03333A (ja)	2011-10-03	2015-07-03	Univ California
CN107205948B (zh) *	2015-01-29	2021-12-14	诺和诺德股份有限公司	包含glp-1激动剂和肠溶衣的片剂
TWI698438B (zh)	2015-03-13	2020-07-11	德商４Ｓｃ製藥公司	Ｋv１.３抑制劑及其醫學應用
TWI701249B (zh)	2015-03-13	2020-08-11	德商４Ｓｃ製藥公司	Ｋv１.３抑制劑及其醫學應用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5453270A (en)	1992-03-30	1995-09-26	Hypermetabolic Therapies, Inc.	Pharmaceutical composition and method for hypermetabolic weight loss
WO1998023639A2 (en)	1996-11-27	1998-06-04	University Of Florida	ShK TOXIN COMPOSITIONS AND METHODS OF USE
AU8052798A (en) *	1997-09-17	1999-04-05	Bachem Bioscience, Inc.	Polypeptide compositions that inhibit potassium channel activity and uses herefor
JP3207823B2 (ja)	1999-04-28	2001-09-10	リノール油脂株式会社	共役リノール酸を有効成分とする褐色脂肪増加剤
US6616944B2 (en)	2000-03-08	2003-09-09	Medinnova Gesellschaft Fur Medizinsche Innovationen Aus Adkademischer Forschung Mbh	Self-assembling colloidal carriers for protein delivery
US6861405B2 (en) *	2001-06-12	2005-03-01	Yale University	Compositions and methods relating to glucose metabolism, weight control, and food intake
EP2474316B1 (en) *	2004-10-07	2016-04-06	The Regents of The University of California	Analogs of shk toxin and their uses in selective inhibition of kv1.3 potassium channels
US7833979B2 (en) *	2005-04-22	2010-11-16	Amgen Inc.	Toxin peptide therapeutic agents
BRPI0616995A2 (pt) *	2005-08-17	2011-07-05	Solvay Pharm Gmbh	composição farmacêutica, e uso de inibidor do canal de potássio kv1.3 na preparação de medicamento
TW201026708A (en) *	2008-12-12	2010-07-16	Solvay Pharm Bv	Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers
IN2014CN03333A (ja)	2011-10-03	2015-07-03	Univ California

2012
- 2012-10-02 IN IN3333CHN2014 patent/IN2014CN03333A/en unknown
- 2012-10-02 CN CN201280049696.6A patent/CN103987408A/zh active Pending
- 2012-10-02 BR BR112014008065A patent/BR112014008065A2/pt not_active IP Right Cessation
- 2012-10-02 CA CA2850357A patent/CA2850357A1/en not_active Abandoned
- 2012-10-02 SG SG11201401193XA patent/SG11201401193XA/en unknown
- 2012-10-02 JP JP2014534641A patent/JP2014531469A/ja active Pending
- 2012-10-02 AU AU2012318736A patent/AU2012318736A1/en not_active Abandoned
- 2012-10-02 RU RU2014117558/15A patent/RU2014117558A/ru not_active Application Discontinuation
- 2012-10-02 WO PCT/US2012/058495 patent/WO2013052507A1/en active Application Filing
- 2012-10-02 EP EP12838795.8A patent/EP2763702A4/en not_active Withdrawn
- 2012-10-02 MX MX2014004029A patent/MX2014004029A/es unknown
- 2012-10-02 US US14/347,602 patent/US20150072940A1/en not_active Abandoned
- 2012-10-02 KR KR1020147012093A patent/KR20140108518A/ko not_active Application Discontinuation
- 2012-10-03 TW TW101136560A patent/TW201321403A/zh unknown
2014
- 2014-04-02 IL IL231873A patent/IL231873A0/en unknown
2015
- 2015-02-13 HK HK15101586.1A patent/HK1201048A1/xx unknown
2016
- 2016-02-22 US US15/049,353 patent/US9878006B2/en active Active

Also Published As

Publication number	Publication date
KR20140108518A (ko)	2014-09-11
SG11201401193XA (en)	2014-05-29
HK1201048A1 (en)	2015-08-21
IL231873A0 (en)	2014-05-28
CA2850357A1 (en)	2013-04-11
RU2014117558A (ru)	2015-11-10
BR112014008065A2 (pt)	2019-09-24
TW201321403A (zh)	2013-06-01
EP2763702A1 (en)	2014-08-13
US20170095530A1 (en)	2017-04-06
WO2013052507A1 (en)	2013-04-11
EP2763702A4 (en)	2015-04-15
CN103987408A (zh)	2014-08-13
US20150072940A1 (en)	2015-03-12
JP2014531469A (ja)	2014-11-27
AU2012318736A1 (en)	2014-05-22
MX2014004029A (es)	2014-08-01
US9878006B2 (en)	2018-01-30

Similar Documents

Publication	Publication Date	Title
EA201490004A1 (ru)	2014-09-30	Применение bifidobacterium lactis bl-04 для лечения заболеваний дыхательных путей
MY160894A (en)	2017-03-31	Oligosaccharide composition for treating skin diseases
MX344238B (es)	2016-12-07	Compuestos de tetrazol y métodos para preparar y usar los mismos.
PH12015500407A1 (en)	2015-09-21	Methods of treating hypertriglyceridemia
MX2021010672A (es)	2021-12-10	Uso de un anticuerpo que tiene la capacidad para ligarse a clnd6 en el tratamiento o prevención de cáncer.
NZ626954A (en)	2016-09-30	Combination therapy of antibodies against human csf-1r and uses thereof
MX2013007189A (es)	2013-07-12	Metodos y composiciones adecuados para manejar glucosa en sangre en animales.
WO2013169864A3 (en)	2014-01-03	TETRAHYDRO[1,8]NAPHTHYRIDINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORƴ AND THE TREATMENT OF DISEASE
IN2014CN03333A (ja)	2015-07-03
MX2013013809A (es)	2013-12-16	Dispositivos expandibles con revestimiento de una composicion de paclitaxel.
BR112013000433A2 (pt)	2016-05-17	diagnóstico e tratamento de câncer de mama
MY173215A (en)	2020-01-06	Acetylcysteine compositions and methods of use thereof
MX2019001977A (es)	2019-06-03	Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados.
BR112014001170A2 (pt)	2017-02-21	cateter, especialmente um cateter permanente, para tratamento de problemas funcionais e/ou doenças da bexiga e/ou próstata
MX364220B (es)	2019-04-16	Metodos de tratamientos de fibrosis.
MX2013008175A (es)	2013-12-16	Composiciones farmacéuticas para suministro tópico de fotosensibilizadores y usos de los mismos.
PH12017500392A1 (en)	2017-07-17	Medical treatments based on anamorelin
MX2014001393A (es)	2014-05-27	3-(bifenil-3-il)-4-hidroxi-8-metoxi-1-azaespiro[4.5]dec-3-en-2-on as sustituidas.
MX2016000220A (es)	2016-08-18	Regulacion del metabolismo de glucosa usando anticuerpos anti-cgrp.
MX2013013808A (es)	2013-12-16	Dispositivos expandibles con revestimiento de una composicion de rapamicina.
MX2015005733A (es)	2016-02-10	Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad.
TN2012000256A1 (en)	2013-12-12	Therapeutic use of protein-polymer conjugates
MX364643B (es)	2019-05-03	USO DEL COMPUESTO FTY720: 2-amino - 2-[2-(4-octilfenil) etil] propano-1,3-diol (fingolimod) EN EL TRATAMIENTO DE PACIENTES CON DIABETES DE TIPO 2.
UA61499U (en)	2011-07-25	massage mat
UA63764U (ru)	2011-10-25	Применение экстракта из листьев сныти обыкновенной в качестве лечебно-профилактического средства с гепатопротекторным действием